Diligence memo · auto-generated · as of July 2, 2026
Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Biostar Pharmaceuticals, Inc. operates in Pharmaceuticals, based in Xianyang, Shaanxi.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Biostar Pharmaceuticals, Inc. has raised $5.7M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.6M on 2009-11-02.
Most recent recorded round closed around 2009-11-18.
Valuation (modeled)modeled
Provath models Biostar Pharmaceuticals, Inc. at approximately $81M (range $1.6M–$633M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Seed Pharmaceuticals companies in 2007–2009 (25 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 1 months.
Last raise 16.6 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 44% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 51% of those peers.
Closest niche peers: Sequoia Pharmaceuticals Inc, Spring Pharmaceuticals, LLC, Oceana Therapeutics, Inc., Supergen Inc, Archer Pharmaceuticals, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.